#United States #New York #Pomerantz LLP #Regencell #RGC

Pomerantz Law Firm Initiates Class Action Against Regencell Bioscience Holdings

Pomerantz LLP, a well-respected law firm known for its expertise in corporate and securities litigation, has filed a class action lawsuit against Regencell Bioscience Holdings Limited and several key officers. The suit, which is currently in the United States District Court for the District of Maryland, alleges significant violations of federal securities laws that have adversely affected investors who purchased Regencell's securities during a specific period.

Key Details of the Lawsuit

The class action claim is brought on behalf of all individuals and entities, excluding the defendants, who acquired securities of Regencell between October 28, 2024, and October 31, 2025. This lawsuit aims to recover damages from the purported misleading statements and actions taken by Regencell and its officials, specifically under sections 10(b) and 20(a) of the Securities Exchange Act of 1934 as well as Rule 10b-5.

Investors who fit the criteria and wish to join the action have until June 23, 2026, to request to be appointed as Lead Plaintiff. Further information, including a copy of the complaint, is accessible through Pomerantz's official website.

Overview of Regencell's Operations

Regencell is described as an emerging bioscience firm that focuses on traditional Chinese medicine for treating attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). While claiming to address the root causes of these neurocognitive disorders, Regencell's actual operational status raises numerous questions. Despite their ambitious goals, the company has reported no revenue and maintains a minimal number of employees dedicated to research and development.

Share Price Volatility

One of the most concerning aspects addressed in the lawsuit is the extraordinary price fluctuation of Regencell's shares. Following a long period of trading below 30 cents, the stock experienced a staggering increase, soaring by 48,650% to hit an all-time high of $78.00 per share on June 17, 2025, only to plummet shortly thereafter. By the time of the lawsuit, the shares were trading significantly lower, raising suspicions regarding the legitimacy of the earlier price spikes.

Pomerantz LLP contends that these erratic price movements are not just the result of ordinary market volatility, but may indicate market manipulation. Regencell's leadership allegedly downplayed this volatility, misinforming investors about the potential risks and failing to disclose the underlying vulnerabilities within the company.

Emerging Investigations

The lawsuit gained further weight when Regencell publicly acknowledged an investigation by the United States Department of Justice in late 2025, following significant trading volatility. This investigation potentially involves inquiries into irregular trading patterns affecting Regencell's ordinary shares, suggesting that the company's executives may not be entirely candid about the risks their investors face.

Pomerantz’s Legacy

Founded by the notable Abraham L. Pomerantz, known for pioneering the class action model, Pomerantz LLP has a long-standing history of advocating for investors' rights. The firm has successfully recovered billions for aggrieved investors and continues its fight against securities fraud and corporate misconduct.

In summary, with the allegations brought forth by Pomerantz LLP, the spotlight is firmly placed on Regencell Bioscience Holdings Limited and its top executives. Investors are urged to pay close attention to developments in this class action as it unfolds, given the implications on their investments and the broader market.

For those looking to learn more or potentially seek participation in this lawsuit, reaching out to Pomerantz LLP is strongly advised. Their continued commitment to transparency and investor rights remains a cornerstone of their operations, as they navigate the complexities of modern securities litigation.